Clinical trial
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
NCT00396370 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00396370 |
|---|---|
| Title | BCG Vaccination Delivered Intradermally, Orally and by Combined Routes |
| Official title | Phase I Studies of the Safety and Immunogenicity of Primary and Secondary BCG Vaccination Delivered Intradermally, Orally and by Combined Routes of Administration in Healthy and Previously Immunologically Naïve Volunteers |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Biological, Other |
| Interventions | BCG strain Connaught, BCG strain Danish, Placebo |
| Enrollment | 69 |
| Start date | Dec 2, 2008 |
| Primary completion | Jul 23, 2012 |
| Completion | Jul 23, 2012 |
| First posted | Nov 6, 2006 |
| Last update posted | Nov 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: